Tag: patent litigation

30-Month Stay: How Litigation Delays Generic Drug Approval

Dec, 11 2025

The 30-month stay under the Hatch-Waxman Act lets brand drug companies delay generic approval by filing patent lawsuits. This legal tool, meant to protect innovation, often extends drug monopolies by years-costing patients billions.

Read Article→

Patent Litigation: How Authorized Generics Undermine Generic Competition

Nov, 27 2025

Authorized generics let brand drug makers launch their own cheaper versions right when independent generics enter the market, undermining price competition and reducing incentives for patent challenges. This practice hurts patients and generic manufacturers - and regulators are fighting back.

Read Article→